Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? (Q34535272)

2 August 2017

1 reference

title

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? (English)

1 reference

2 August 2017

Howell A

1

1 reference

2 August 2017

Howell SJ

series ordinal

2

1 reference

2 August 2017

Clarke R

series ordinal

3

1 reference

2 August 2017

Anderson E

series ordinal

4

1 reference

2 August 2017

publication date

1 December 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

2 August 2017

published in

1 reference

2 August 2017

volume

79

1 reference

2 August 2017

issue

1-5

1 reference

2 August 2017

page(s)

227-237

1 reference

Influence of Synthetic Oestrogens on Advanced Malignant Disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Synthetic oestrogens in mammary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

New endocrine therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Preliminary trial of aminoglutethimide in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Abnormal regulation of the oestrogen receptor in benign breast lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Lessons from the use of aromatase inhibitors in the neoadjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900140-6

7 January 2021

10.1016/S0960-0760(01)00140-6

Identifiers

DOI

1 reference

release_fcagv7uxtzauto7vdq2jdg5sdu

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fcagv7uxtzauto7vdq2jdg5sdu

24 November 2022

mapped directly with Wikidata item

1 reference